Clinical Trial Detail

NCT ID NCT03878927
Title CPX-351+GO in Subjects 55 Years Old, or Older, With AML (CPX GO)
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements No
Sponsors Weill Medical College of Cornell University
Indications

acute myeloid leukemia

Therapies

CPX-351 + Gemtuzumab ozogamicin

Age Groups: adult senior

No variant requirements are available.